Stephen B. Baylin

Last updated

Stephen Bruce Baylin is the deputy director and associate director for research at the Sidney Kimmel Comprehensive Cancer Center and Virginia and D.K. Ludwig Professor for Cancer Research and medicine and chief of cancer biology of the Johns Hopkins University School of Medicine. His research focus is epigenetics in the development of cancer, and he was one of the first researchers in this field in the 1980s.

Baylin received his BS and MD from Duke University in 1968. [1] Baylin started his research against cancer during the Vietnam war. "They called us the Yellow Berets — MDs who opted to do their public service by engaging in research at the National Institutes of Health. I was interested in an inherited form of thyroid cancer, called medullary thyroid carcinoma." He published his findings in relation to that research in the New England Journal of Medicine in 1970. [2] [3] He joined the faculty at Johns Hopkins in 1974. In 1991, he was appointed chief of tumor biology.

He and Peter Laird were the original investigators of the epigenetic portion of The Cancer Genome Atlas. [2] He co-leads, with Peter Jones, a Stand Up To Cancer team science initiative in regulatory epigenetics, the VARI-SU2C Epigenetics Dream Team, and as part of this has an appointment to the faculty of the Van Andel Research Institute. [4] [5]

In 2010, he was featured in GQ's "Rock Stars of Science" to publicize biomedical researchers. [2]

Awards

Related Research Articles

<span class="mw-page-title-main">Victor Velculescu</span>

Victor E. Velculescu is a Professor of Oncology and Co-Director of Cancer Biology at Johns Hopkins University School of Medicine. He is internationally known for his discoveries in genomics and cancer research.

<span class="mw-page-title-main">Van Andel Institute</span> Non-profit organisation in the USA

Van Andel Institute(VAI) is a 501(c)(3) nonprofit biomedical research and science education organization in Grand Rapids, Michigan. VAI was founded by Jay and Betty Van Andel in 1996.

<span class="mw-page-title-main">Joseph F. Fraumeni Jr.</span> American physician and cancer researcher

Joseph F. Fraumeni Jr. is an American physician and cancer researcher. Born in Boston, he received an A.B. from Harvard College, an M.D. from Duke University, and an M.Sc. in epidemiology from the Harvard School of Public Health. He completed his medical residency at Johns Hopkins Hospital and Memorial Sloan Kettering Cancer Center. He then joined the National Cancer Institute at the National Institutes of Health in 1962 as a commissioned officer of the U.S. Public Health Service, becoming the founding Director of the Division of Cancer Epidemiology and Genetics in 1995. He stepped down from this position in 2012 to become a senior investigator and advisor to the National Cancer Institute.

<span class="mw-page-title-main">Charles Sawyers</span> American physician-scientist (born 1959)

Charles L. Sawyers is a Howard Hughes Medical Institute (HHMI) investigator who holds the Marie-Josée and Henry R. Kravis Chair of the Human Oncology and Pathogenesis Program (HOPP) at Memorial Sloan Kettering Cancer Center (MSK). HOPP is a program created in 2006 that comprises researchers from many disciplines to bridge clinical and laboratory discoveries.

Owen Witte is an American physician-scientist at the University of California, Los Angeles. He is a University Professor of microbiology, immunology and molecular genetics in the David Geffen School of Medicine at UCLA, founding director emeritus of the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, and the UC Regents’ David Saxon Presidential Chair in developmental immunology (1989–present). Witte is also a Howard Hughes Medical Institute investigator (1986–2016) and a member of the President's Cancer Panel, the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, and the Cancer Research Academy of the AACR. He serves on numerous editorial boards and scientific advisory boards for academic centers and biotechnology companies.

<span class="mw-page-title-main">William Kaelin Jr.</span> American Nobel Laureate, Professor of Medicine at Harvard University

William G. Kaelin Jr. is an American Nobel laureate physician-scientist. He is a professor of medicine at Harvard University and the Dana–Farber Cancer Institute. His laboratory studies tumor suppressor proteins. In 2016, Kaelin received the Albert Lasker Award for Basic Medical Research and the AACR Princess Takamatsu Award. He also won the Nobel Prize in Physiology or Medicine in 2019 along with Peter J. Ratcliffe and Gregg L. Semenza.

Andrew Paul Feinberg is the director of the Center for Epigenetics, chief of the Division of Molecular Medicine in the Department of Medicine, and the King Fahd Professor of Medicine, Oncology, Molecular Biology & Genetics in the School of Medicine at Johns Hopkins University.

<span class="mw-page-title-main">Carl H. June</span> American immunologist and oncologist

Carl H. June is an American immunologist and oncologist. He is currently the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine of the University of Pennsylvania. He is most well known for his research on T cell therapies for the treatment of several forms of cancers. In 2020 he was elected to the American Philosophical Society.

Carlos L. Arteaga is the Associate Director for Clinical Research, director of the Center for Cancer Targeted Therapies, and professor of Cancer Biology and Medicine at Vanderbilt-Ingram Cancer Center. In 2014–2015, he was the president of the American Association for Cancer Research.

Gordon B. Mills is the Wayne and Julie Drinkward Endowed Chair in Precision Oncology, Director of Precision Oncology, Director of SMMART Trials and Professor in Cell, Development and Cancer Biology in the Knight Cancer Institute at Oregon Health & Science University.

<span class="mw-page-title-main">Daniel Von Hoff</span> American oncologist

Daniel D. Von Hoff is the physician in chief and director of translational research at Translational Genomics Research Institute (TGen), and current Virginia G. Piper Distinguished Chair for Innovative Cancer Research at HonorHealth Clinical Research Institute. He is also a professor of medicine at the Mayo Clinic and medical director of research as well as chief scientific officer at US Oncology. He is most notable for his work in targeted therapies for the treatment of cancer. He led the development of gemcitabine, and has several drugs in development.

<span class="mw-page-title-main">Curtis C. Harris</span> American cancer researcher

Curtis. C. Harris is the head of the Molecular Genetics and Carcinogenesis Section and chief of the Laboratory of Human Carcinogenesis at the Center for Cancer Research of the National Cancer Institute, NIH.

Bruce Allan Chabner is an American medical oncologist and researcher who worked at the National Cancer Institute and now is a professor of medicine at Harvard Medical School. He is also the director of clinical research at the Cancer Center at Massachusetts General Hospital. His expansive research of cancer pharmacology most notably includes his contributions to developing anti-folate drugs for the treatment of cancer. His work at NIH led to the development of Taxol, a commonly prescribed breast cancer drug.

Nita Ahuja is a surgeon and the Chair of the Department of Surgery at Yale School of Medicine and Surgeon-in-Chief of Surgery at Yale New Haven Hospital. She is the first woman ever to serve as Chair of Surgery in Yale in its >200 year history. Before taking this position she was the first woman ever to be the Chief of Surgical Oncology at Johns Hopkins Hospital, Baltimore, USA. Ahuja researches in the field of epigenetics and is a passionate advocate of clinician scientist. She also served as the director of Sarcoma and peritoneal surface malignancy program. She is a surgeon-scientist and her research has been cited more than 11,000 times in scientific literature.

Guillermina 'Gigi' Lozano is an American geneticist. She is a Professor and Hubert L. Olive Stringer Distinguished Chair in Oncology in Honor of Sue Gribble Stringer at the University of Texas MD Anderson Cancer Center, Houston, Texas. Lozano is recognised for her studies of the p53 tumour suppressor pathway, characterising the protein as a regulator of gene expression and that is disturbed in many cancers. She was the first to recognize that the p53 gene encoded a transcriptional activator of other genes Her lab has made significant contributions by developing and analyzing mouse models to study the activities of mutant p53, revealing how these mutations drive tumor development and progression. She also found out how the Mdm2 and Mdm4 proteins work in the body, especially in stopping cancer and controlling p53. This research suggested that blocking Mdm2/4 could be a new way to treat cancer.

Kornelia Polyak is a professor of medicine at Harvard Medical School and an internationally recognized breast cancer expert.

Roy S. Herbst is an American oncologist who is the Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research at Yale Cancer Center and Yale School of Medicine in New Haven, Connecticut.

James R. Downing is an American clinical executive. He is the president and chief executive officer of St. Jude Children's Research Hospital.

<span class="mw-page-title-main">Chi Van Dang</span> Hematological oncologist

Chi Van Dang is a hematological oncologist and researcher, currently serving as the Scientific Director of Ludwig Institute for Cancer Research. He is known for his research on genetics, the MYC gene and the cellular energy metabolism of cancer.

Philip Greenberg is a professor of medicine, oncology, and immunology at the University of Washington and head of program in immunology at the Fred Hutchinson Cancer Research Center. His research is centered around T cell biology and therapeutic cell therapies. He is a co-founder of Juno Therapeutics.

References

  1. "Stephen B. Baylin, M.D." hopkinsmedicine.org. Retrieved 2016-12-25.
  2. 1 2 3 "An Epi Phenomenon | The Scientist Magazine". Archived from the original on 2016-12-25. Retrieved 2016-12-25.
  3. "Stand Up To Cancer Stephen B. Baylin, M.D." standup2cancer.org. Retrieved 2016-12-25.
  4. "Stephen Bruce Baylin, MD | Johns Hopkins - Institute of Genetic Medicine". igm.jhmi.edu. Retrieved 2016-12-25.
  5. "VARI-SU2C Epigenetics Dream Team Lead Investigator Bio - VARI-SU2C Epigenetics Dream Team". varisu2cepigeneticsdreamteam.vai.org. Retrieved 2016-12-25.